Search Results - "Comont, T"

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study by Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.

“…Background: Nivolumab and pembrolizumab, two PD1 inhibitors, trigger immune-related adverse events in approximately 50% of patients. Our objective was to…”
Get full text

Actualités de l'épidémiologie du purpura thrombopénique immunologique de l'adulte : Impact pour la pratique clinique by Moulis, G, Comont, T, Adoue, D

“…New insights into immune thrombocytopenia (ITP) epidemiology in adult patients highlight three main outcomes of morbidity and mortality: bleeding, infection…”
Get full text

Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults by Piel‐Julian, M.‐L., Mahévas, M., Germain, J., Languille, L., Comont, T., Lapeyre‐Mestre, M., Payrastre, B., Beyne‐Rauzy, O., Michel, M., Godeau, B., Adoue, D., Moulis, G., Alric, L., Arista, S., Astudillo, L., Balardy, L., Betrian, S., Bonnet, D., Borel, C., Brechemier, D., Brun, N., Carreiro, M., Castel, B., Caudrelier, L., Cougoul, P., Danu, A., Delavigne, K., Dingremont, C., Faurie, T., Gaches, F., Gaspard, M.‐H., Gaudin, C., Godel‐Labouret, A., Giraud, P., Hadj‐Khelifa, S., Hebraud, B., Khatibi, S., Leplay, L., Leveneur, Y., Limal, N., Ollier, S., Madaule, S., Marchou, B., Martel, C., Martin‐Blondel, G., Montane De La Roque, P., Michaud, M., Moeglin, J., Nuccio, F., Prudhomme, L., Pugnet, G., Recher, C., Remy, V., Sailler, L., Sire, S., Sommet, A., Tavitian, S., Thiercelin‐Legrand, M.‐F., Vaillant, W.

“…Essentials Risk factors of bleeding in adult immune thrombocytopenia are not known. This multicenter study assessed risk factors of bleeding at immune…”
Get full text

Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study by Michel, M., Saïr, M., Rivière, E., Moulis, G., Comont, T., Costedoat‐Chalumeau, N., Pouchelon, C., Boutboul, D., Benyamine, A., Bert, A., Jeandel, P. ‐Y., Hamrouni, S., Belfeki, N., Lobbes, H., Dossier, A., Gobert, D., Mahevas, M., Godeau, B., Gallien, Y., Ebbo, M.

Get full text

Multiple strokes in a 17-year-old woman by Duhamel, N, Queyrel, V, Tieulié, N, Comont, T

Get full text

Relevance of Next Generation Sequencing in Helping Diagnosis of Unexplained Cytopenias by Juvin, P.Y, Laclau, S, Prade, N, Comont, T, Delabesse, E, Rauzy, O. Beyne

Get full text

Immune-related adverse events after immune checkpoints inhibitors in 2019: An update by Comont, T, Belliere, J, Sibaud, V, Alric, L, Meyer, N, Mazières, J, Caron, P, Acket, B, Michot, J-M, Beyne-Rauzy, O, Lambotte, O

“…Use of checkpoint inhibitors to treat cancer was one of the most important revolution these last years and an increasing number of new types of tumors is…”
Get full text

Management of myelodysplastic syndromes in 2019: An update by Comont, T, Delavigne, K, Cougoul, P, Bertoli, S, Delabesse, E, Fenaux, P, Beyne-Rauzy, O

“…Myelodysplastic syndromes are a heterogeneous group of clonal myeloid disorders characterized by peripheral cytopenias and an increased risk of progression to…”
Get full text

New insights into the epidemiology of immune thrombocytopenia in adult patients: Impact for clinical practice by Moulis, G., Comont, T., Adoue, D.

“…New insights into immune thrombocytopenia (ITP) epidemiology in adult patients highlight three main outcomes of morbidity and mortality: bleeding, infection…”
Get full text

Acute hepatitis E infection associated with Guillain-Barré syndrome in an immunocompetent patient by Comont, T, Bonnet, D, Sigur, N, Gerdelat, A, Legrand-Abravanel, F, Kamar, N, Alric, L

“…Hepatitis E virus (HEV) infection is now recognized to be an emerging autochthonous disease in several countries. There have been several reports of…”
Get full text

94 IMPACT OF COMORBIDITIES ON OVERALL SURVIVAL IN THE ELDERLY WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA TREATED BY AZACITIDINE by Brechemier, D, Bertoli, S, Comont, T, Balardy, L, Recher, C, Lauwers-Cances, V, Beyne-Rauzy, O

Get full text

91 IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE by Brechemier, D, Comont, T, Bertoli, S, Dutertre, M, Recher, C, Adoue, D, Beyne-Rauzy, O

Get full text

92 IMPACT OF COMORBIDITIES AND GERIATRIC ASSESSMENT IN HIGH RISK MYELODYSPLASTIC SYNDROMES OVER 75 YEARS TREATED WITH AZACITIDINE by Brechemier, D, Comont, T, Bertoli, S, Lozano, S, Gerard, S, Adoue, D, Lauwers-Cances, V, Beyne-Rauzy, O

Get full text

163 Extra-medullary localization in high risk myelodysplastic syndromes: A new modality of relapse after therapy by Comont, T, Gaudre, N, Moeglin, J, Cougoul, P, Leveneur, Y, Adoue, D, Récher, C, Beyne-Rauzy, O

Get full text

157 Impact on quality of life of outpatient treatment in high risk myelodysplastic syndromes: Results of a pilot study by Sekkaï, V, Thiercelin-Legrand, M.-F, Comont, T, Gaudre, N, Oilier, S, Récher, C, Beyne-Rauzy, O

Get full text

213 Thrombotic events in del(5q) associated myelodysplastic syndromes by Comont, T, Challan-Belval, T, Delavigne, K, Ollier, S, Gaudre, N, Moeglin, J, Adoue, D, Beyne-Rauzy, O

Get full text

338 Home blood transfusions: feasibility and safety, three years of experience in myelodysplastic syndromes by Boulanger, P, Comont, T, Moeglin, J, Thiercelin-Legrand, M.-F, Cougoul, P, Récher, C, Beyne-Rauzy, O

Get full text

186 Interstitial lung disease: Uncommon but potentially severe effect of hypomethylating agents by Prévot, G, Delavigne, K, Cougoul, P, Comont, T, Brechemier, D, Prudhomme, L, Adoue, D, Beyne-Rauzy, O

Get full text

367 Durable response after lenalidomide discontinuation in del(5q) low risk MDS by Comont, T, Delavigne, K, Challan-Belval, T, Ollier, S, Brechemier, D, Adoue, D, Beyne-Rauzy, O

Get full text

Hépatite E aiguë associée à un syndrome de Guillain-Barré chez un patient immunocompétent by Comont, T., Bonnet, D., Sigur, N., Gerdelat, A., Legrand-Abravanel, F., Kamar, N., Alric, L.

“…L’infection par le virus de l’hépatite E (VHE) est désormais reconnue comme une maladie autochtone émergente dans plusieurs régions du monde. Des…”
Get full text